Correction: Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8098940/
https://www.ncbi.nlm.nih.gov/pubmed/33941652
http://dx.doi.org/10.1136/jitc-2020-000891corr1
Descripción
Sumario:

Ejemplares similares